Printer Friendly

Sanofi wins US FDA approval for the expanded use of Soliqua 100/33 as add-on to diet and exercise for adults with type 2 diabetes.

M2 PHARMA-February 28, 2019-Sanofi wins US FDA approval for the expanded use of Soliqua 100/33 as add-on to diet and exercise for adults with type 2 diabetes


Biopharmaceutical company Sanofi revealed on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for the expanded use of Soliqua 100/33 (insulin glargine and lixisenatide injection) 100 units/ml and 33 mcg/ml.

Soliqua 100/33, which was previously approved for use as an add-on to diet and exercise in adults with type 2 diabetes who are uncontrolled on long-acting insulin or lixisenatide, can now be prescribed for patients uncontrolled on oral antidiabetic medicines, added the company.

According to the company, Soliqua 100/33 is an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine and lixisenatide, which may improve blood sugar (glucose) control in adults with type 2 diabetes when used with diet and exercise.

This US FDA's approval, which was based on data from the company's LixiLan-O clinical trial in adults with type 2 diabetes uncontrolled with metformin and/or a second oral antidiabetic therapy, now showed that treatment with Soliqua 100/33 led to significantly greater reductions in blood sugar levels compared with insulin glargine and lixisenatide. In addition, significantly more patients reached their target blood sugar levels with Soliqua 100/33 compared with insulin glargine or lixisenatide.

In conjunction, the company will continue offering its savings programme for Soliqua 100/33 which can limit out-of-pocket expenses sometimes to USD0 for all commercially insured patients regardless of formulary status on an insurance plan or income level.

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 28, 2019
Previous Article:IBSA Pharma Inc to market the only US FDA-approved liquid levothyroxine formulation Tirosint-SOL for treating hypothyroidism.
Next Article:WuXi Biologics wins US FDA's breakthrough therapy designation for AT-GAA in late onset Pompe disease.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters